Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer to Lead Clinical Development of Simufilam for TSC-Related Epilepsy

Reuters

2025/08/07

Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer to Lead Clinical Development of Simufilam for TSC-Related Epilepsy

Cassava Sciences, Inc. has appointed Dr. Joseph Hulihan as their new Chief Medical Officer. Dr. Hulihan will focus on the clinical development of simufilam, a treatment candidate for Tuberous Sclerosis Complex-related epilepsy, dedicating about half of his professional time to the role. A clinical study for simufilam is expected to begin in the first half of 2026. Dr. Hulihan brings over 25 years of experience in the development of therapeutics for neurological disorders.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cassava Sciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9507584-en) on August 07, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2557550874"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2557550874\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2557550874?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-07 19:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2557550874","market":"fut","top_or_hot":-1,"title":"Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer to Lead Clinical Development of Simufilam for TSC-Related Epilepsy","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer to Lead Clinical Development of Simufilam for TSC-Related Epilepsy\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Cassava Sciences, Inc. has appointed Dr. Joseph Hulihan as their new Chief Medical Officer. Dr. Hulihan will focus on the clinical development of simufilam, a treatment candidate for Tuberous Sclerosis Complex-related epilepsy, dedicating about half of his professional time to the role. A clinical study for simufilam is expected to begin in the first half of 2026. Dr. Hulihan brings over 25 years of experience in the development of therapeutics for neurological disorders.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/SAVA\">Cassava Sciences Inc</a>. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9507584-en) on August 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer to Lead Clinical Development of Simufilam for TSC-Related Epilepsy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer to Lead Clinical Development of Simufilam for TSC-Related Epilepsy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-07 19:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer to Lead Clinical Development of Simufilam for TSC-Related Epilepsy\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Cassava Sciences, Inc. has appointed Dr. Joseph Hulihan as their new Chief Medical Officer. Dr. Hulihan will focus on the clinical development of simufilam, a treatment candidate for Tuberous Sclerosis Complex-related epilepsy, dedicating about half of his professional time to the role. A clinical study for simufilam is expected to begin in the first half of 2026. Dr. Hulihan brings over 25 years of experience in the development of therapeutics for neurological disorders.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/SAVA\">Cassava Sciences Inc</a>. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9507584-en) on August 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SAVA","symbol_name":"Cassava Sciences Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250807:nNDL2jv6BG:1","article_id":"2557550874","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2557550874","pubTimestamp":1754566240,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer to Lead Clinical Development of Simufilam for TSC-Related Epilepsy. Cassava Sciences, Inc. has appointed Dr. Joseph Hulihan as their new Chief Medical Officer. Dr. Hulihan will focus on the clinical development of simufilam, a treatment candidate for Tuberous Sclerosis Complex-related epilepsy, dedicating about half of his professional time to the role. A clinical study for simufilam is expected to begin in the first half of 2026. Dr. Hulihan brings over 25 years of experience in the development of therapeutics for neurological disorders.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cassava Sciences Inc. published the original content used to generate this news bri","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"SAVA":"Cassava Sciences Inc","NDAQ":"纳斯达克OMX交易所"},"translate_title":"Cassava Sciences任命Joseph Hulihan博士为首席医疗官，领导Simufilam治疗TSC相关癫痫的临床开发","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SAVA":0.9,"NDAQ":0.9},"content_text":"Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer to Lead Clinical Development of Simufilam for TSC-Related Epilepsy\n    \n\n        Cassava Sciences, Inc. has appointed Dr. Joseph Hulihan as their new Chief Medical Officer. Dr. Hulihan will focus on the clinical development of simufilam, a treatment candidate for Tuberous Sclerosis Complex-related epilepsy, dedicating about half of his professional time to the role. A clinical study for simufilam is expected to begin in the first half of 2026. Dr. Hulihan brings over 25 years of experience in the development of therapeutics for neurological disorders.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cassava Sciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9507584-en) on August 07, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}